08:29 AM EDT, 07/11/2025 (MT Newswires) -- Helix Acquisition (HLXB), a special purpose acquisition company, and TheRas, doing business as BridgeBio Oncology Therapeutics, said Friday that their registration statement on Form S-4 for the proposed business combination has been declared effective by the US Securities and Exchange Commission.

The companies said they plan to complete the merger next month, and that the extraordinary general meeting of Helix stockholders will take place on Aug. 4.